Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena. The expansion is prompted by a growing demand for Seqirus influenza vaccines and the launch of a new cell-based quadrivalent influenza vaccine this season.
The premises were officially opened during a ribbon-cutting ceremony, attended by the local authorities and other stakeholders. Maura Cambiaggi, General Manager of Seqirus Italy; Russell Basser, Chief Scientist, Seqirus; and Emanuele Montomoli, professor at the University of Siena and founder of VisMederi - a company Seqirus entered into a collaboration agreement with in 2018 - all spoke during the ceremony before attendees enjoyed a tour of the new space.
Seqirus has been active in Italy since 2015, when CSL Limited – a leading global biotechnology company based in Australia – acquired the influenza vaccine business from another global pharmaceutical company. Today, Seqirus is a global provider of seasonal influenza vaccines as well as a transcontinental partner in pandemic preparedness.
Maura Cambiaggi, General Manager, Italy, Seqirus, commented:
“I am proud to inaugurate this new and beautiful location for our company. In fact, it is not just a building, but the affirmation of Seqirus’ presence in our Country, not only from a commercial perspective, but above all in terms of our daily commitment to the fight against influenza.
Russell Basser, Chief Scientist, Seqirus, added:
“We have a talented Italian team who have a long history of partnership with local health authorities and institutions, in order to protect the population from the dangers of influenza. The new headquarters will see our growing team move into a new, flexible and technically equipped work environment, designed to allow them to continue to be on the front line against influenza.”
Speaking at the ceremony, Professor Emanuele Montomoli, added:
“Thanks to the strategic collaboration between VisMederi and Seqirus, the tradition of flu prevention continues in Italy – and specifically in Siena. These months, we are focusing on the definition of innovative processes for the development of new-generation influenza vaccines, of which Seqirus’ new quadrivalent on cell culture already is a milestone. Now it’s important to continue the dialogue, especially with local and national institutions, in order to ensure everyone, receive the most appropriate vaccine in relation to their age and specific clinical status.”
###
Media Contact
Robert Sutherland
07917 551 666
About Seqirus
Seqirus, a subsidiary of CSL Limited, was established on 31 July 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries.
For more information visit www.seqirus.com.
About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 60 countries and employs more than 22,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
For more information about CSL Limited, visit www.csl.com.